Evidence map›Paper›PMID 42003575›Full record

ArticleAntimicrobial agents and chemotherapy2026

Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of

Hilliard L Kutscher, Maria Tamblin, Patrick Kenney, Jessica L Reynolds

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hilliard L Kutscher *Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
Maria Tamblin *Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
Patrick KenneyAdult and Pediatric Infectious Disease, The State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0000-0003-0410-5224
Jessica L ReynoldsDivision of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0000-0001-5188-6786

Funding

National Institute of Allergy and Infectious Diseases 1R01AI129649, 1R21AI179228
6 · The paper itself

Abstract

Prolonged daily tuberculosis therapy contributes to toxicity, poor adherence, and drug resistance. We developed rifampin (RIF)-loaded β-glucan-chitosan-poly (lactic co-glycolic) acid nanoparticles (β-C-P nanoparticles) for weekly pulmonary delivery and evaluated a hybrid dosing regimen in a BALB/c

Indexed as

Antitubercular Agentsbeta-GlucansChitosanMycobacterium tuberculosisNanoparticlesAdministration, OralAnimalsFemaleIsoniazidLungMiceMice, Inbred BALB CPolylactic Acid-Polyglycolic Acid CopolymerPyrazinamideRifampinAntitubercular Agentsbeta-GlucansChitosanIsoniazidPolylactic Acid-Polyglycolic Acid CopolymerPyrazinamideRifampinisoniazidMycobacterium tuberculosisnanoparticlesPLGApyrazinamiderifampintuberculosisβ-glucan

Identifiers

PMID42003575
PMCPMC13231870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.